Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside
Record Stock Surge on Phase 3 Breakthrough Praxis Precision Medicines shares skyrocketed on October 16, 2025, after the biotech reported game-changing Phase 3 trial results for its essential tremor drug. The stock closed that Thursday at $162.71, up over 183% in a single day medcitynews.com. Earlier that morning, Praxis announced that ulixacaltamide – its experimental therapy for essential tremor – had succeeded in two pivotal late-stage studies. The news sent PRAX stock soaring more than threefold before the opening bell reuters.com reuters.com, smashing its previous highs. By midday, Reuters estimated Praxis was on track to add about $2.67 billion to its market